tiprankstipranks
Moderna initiated with an Outperform at RBC Capital
The Fly

Moderna initiated with an Outperform at RBC Capital

RBC Capital analyst Luca Issi initiated coverage of Moderna with an Outperform rating and $200 price target. The "COVID cliff" and its near-term impact on the profit & loss statement is "well appreciated," said the firm, which adds that the company’s RSV vaccine data was "impressive" and contends that Moderna can differentiate by bundling this offering with its COVID vaccine.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on MRNA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles